Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790168 | 0.85 | PARP10 (0.47) | PARP10MKNK1MKNK2CHEK2FYN | |
| SCHEMBL3788399 | 0.85 | CHEK2 (0.53) | PARP10MKNK1MKNK2CHEK2FYN | |
| SCHEMBL14972617 | 0.84 | PARP10 (0.46) | PARP10MKNK1MKNK2CHEK2FYN | |
| SCHEMBL3787112 | 0.84 | MAPT (0.49) | RELA | |
| SCHEMBL8226965 | 0.82 | MAPK14 (0.53) | PARP10MKNK1MKNK2MAPK14CHEK2 | |
| SCHEMBL3791419 | 0.81 | PARP1 (0.42) | MKNK2MAPK14MAP4K4IKBKBPDK2 | |
| SCHEMBL1708791 | 0.78 | KMT2A (0.48) | CHEK2MAP4K4RELA | |
| Benzidine SCHEMBL9460959 | 0.78 | PARP10 (0.65) | PARP10MKNK1MKNK2MAP4K4IKBKB | |
| SCHEMBL3786517 | 0.78 | PARP10 (0.65) | PARP10MKNK1MKNK2MAP4K4IKBKB | |
| SCHEMBL31511258 | 0.77 | IKBKB (0.40) | PARP10MKNK1MKNK2CHEK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | PARP10 1861/4885MKNK1 3527/4885MKNK2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.